^
Association details:
| Biomarker: | EGFR mutation + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
12P-A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs
Published date:
03/23/2022
Excerpt:
NSCLC patients with activated EGFR mutations after failure of EGFR TKIs were recruited...The treatment is to combine atezolizumab, bevacizumab (7.5 mg/kg), and pemetrexed-platinum...ORR was 42.1%, and the DCR was 100%. Median PFS was 10.2 months, and OS was not mature yet. Patients with PD-L1 ≥ 1% have a higher ORR than those with PD-L1<1% (85.7% vs. 16.7%; p = 0.003). Compared with the historical control group (Bev/Pem/Platin) (n= 53), the experimental treatment (Atezo/Bev/Pem/Platin) showed significant benefits in DCR (100.0% vs. 64.2%; p¼0.002)and PFS (10.2 vs. 5.9 mo.; p= 0.007)...
Secondary therapy:
cisplatin + pemetrexed; carboplatin + pemetrexed
DOI:
https://doi.org/10.1016/j.annonc.2022.02.021
Trial ID:
